We highly recommend enabling Javascript while using the BlackBoxRX site.


Serious Harm with IV Administration of Oral Product

  • Do not administer Nimotop intravenously or by by other parenteral routes. Deaths and serious, life-threatening adverse events have occurred when the contents of Nimotop capsules have been injected parenterally. (see WARNINGS and DOSAGE AND ADMINISTRATION).

FDA and Industry Communications

Package Inserts


Additional Information

Updated January 2018